Abram Scientific has been awarded a Defense Advanced Research Projects Agency (DARPA) contract worth up to $8.3m, setting the company up with funds to advance its blood coagulation testing platform.
The California-based company’s CoagCare is a point-of-care (POC) diagnostic designed to assess and characterise blood coagulation status within 10 minutes and to provide actionable information that is intended to help improve clinical outcomes.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to Abram, CoagCare overcomes the limitations of conventional technologies to measure blood coagulation, since other approaches such as thromboelastography can take between 30-60 minutes to complete.
CoagCare is still pending US Food and Drug Administration (FDA) clearance. Abram’s latest funding from DARPA, however, which follows its completion of a $10.75m Series A financing round in February 2026, leaves the company with a burgeoning cash runway to support a regulatory filing with the FDA.
DARPA is a research and development agency of the US Department of Defense responsible for creating breakthrough technologies for national security. Abram gained the contracts due to its technology’s use for military units and first responders in resource-limited environments.
DARPA’s funds were awarded to Abram under its resuscitation and prevention of ischemia-induced dysfunction (RAPIID) programme. The proceeds are intended to accelerate the POC diagnostic’s development towards FDA clearance but also to optimise CoagCare to support the administration of shelf-stable blood analogue components. The funding will also support the establishment of manufacturing capabilities for the CoagCare metre and disposable test card, alongside the development of a military-focused system design that builds on the platform’s portability.
Terms surrounding the contract, however, and which aspects could affect the contract’s total awarded funds, were not immediately clear. DARPA latest funding for Abram follows a $2m tranche it awarded to the company in October 2025 that was specifically intended to support its efforts to miniaturise CoagCare.
Abram’s founder and CEO, Abhishek Ramkumar, commented: “Rapid access to actionable coagulation information can be critical for saving lives in trauma care, when every minute matters.
“This DARPA award recognises the importance of bringing laboratory-quality coagulation information closer to the patient and supports our efforts to develop a platform that can ultimately serve both military and civilian medicine.”
